Amir Anthony Jazaeri, M.D.
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
About Dr. Amir Anthony Jazaeri
Dr. Jazaeri is the Vice Chair for Clinical Research and the Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center. He... obtained his Bachelor and Medical degrees from the University of Virginia and completed his residency in Obstetrics and Gynecology at the same institution. He completed his fellowship in Gynecologic Oncology at the National Cancer Institute and MD Anderson Cancer Center. Since his recruitment in 2014, he has established a broad base immunotherapy program for gynecologic cancers that include adoptive cell therapies, vaccines, and immune checkpoint inhibitor investigations. His other areas of research interest include innovative clinical trial designs and translational research for identification of novel immunotherapy targets for gynecologic cancers.
Present Title & Affiliation
Primary Appointment
Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1996 | University of Virginia School of Medicine, Charlottesville, VA, USA, MD, Doctor of Medicine |
| 1992 | University of Virginia, Charlottesville, VA, USA, BA, Interdisciplinary Studies |
Postgraduate Training
| 2002-2004 | Clinical Fellowship, Gynecologic Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX |
| 2000-2002 | Research Fellowship, Gynecologic Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD |
| 1996-2000 | Clinical Residency, Obstetrics and Gynecology, University of Virginia, Charlottesville, VA |
Board Certifications
| 2007 | Gynecologic Oncology American Board of Obstetrics and Gynecology |
| 2005 | American Board of Obstetrics and Gynecology |
Selected Publications
Peer-Reviewed Articles
- Hinchcliff E, Gunther J, Ponnie AE, Bednarski B, Onstad M, Shafer A, Frumovitz M, Jazaeri A, Urbauer D, Bodurka DC. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. J Cancer Educ 37(3):615-620, 2022. e-Pub 2020. PMID: 32839894.
- How JA, Patel A, Jazaeri AA. Immuno-Oncology for Gynecologic Malignancies. Adv Exp Med Biol 1342:193-232, 2021. PMID: 34972966.
- Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol 158(3):570-575, 2020. e-Pub 2020. PMID: 32534809.
- Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol 157(1):161-166, 2020. e-Pub 2020. PMID: 31924334.
- Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep 31(2):107502, 2020. PMID: 32294438.
- How J, Patel A, Jazaeri AA. Immuno-oncology for Gynecologic Malignancies. Adv Exp Med Biol 1244:149-182, 2020. PMID: 32301014.
- Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother. e-Pub 2019. PMID: 31602489.
- Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, Difeo A, Scacheri PC, Adli M. Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer. Cancer Res 79(18):4599-4611, 2019. e-Pub 2019. PMID: 31358529.
- Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri AA, Jhingran A, Schmeler KM, Daniel CR, Klopp A. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. e-Pub 2019. PMID: 31500892.
- Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri AA. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. e-Pub 2019. PMID: 31515669.
- Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA. B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecol Oncol Rep 29:94-97, 2019. e-Pub 2019. PMID: 31467959.
- Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7(1):118, 2019. e-Pub 2019. PMID: 31053161.
- Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri AA, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7(1):93, 2019. e-Pub 2019. PMID: 30940209.
- Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 6(7(1)):31, 2019. e-Pub 2019. PMID: 30728076.
- Roelands J, Garand M, Hinchcliff E, Ma Y, Shah P, Toufiq M, Alfaki M, Hendrickx W, Boughorbel S, Rinchai D, Jazaeri A, Bedognetti D, Chaussabel D. Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. Front Immunol 10:2410, 2019. e-Pub 2019. PMID: 31681299.
- Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and Outcomes of Patients with Recurrent Ovarian Cancer Undergoing Early Phase Immune Checkpoint Inhibitor Clinical Trials. Gynecol Oncol 151(3):407-413, 2018. e-Pub 2018. PMID: 30366646.
- Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A Practical Guide for the Safe Implementation of Early Phase Drug Development and Immunotherapy Program in Gynecologic Oncology Practice. Gynecol Oncol 151(2):374-380, 2018. e-Pub 2018. PMID: 30213435.
- Johnson C, Jazaeri AA . Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Clin Ther 40(3):389-394, 2018. e-Pub 2018. PMID: 29519715.
- Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol 9:2102, 2018. e-Pub 2018. PMID: 30283446.
- Kumar P, Dillon LW, Shibata Y, Jazaeri AA , Jones DR, Dutta A. Normal and Cancerous Tissues Release extrachromosomal circular DNA (eccDNA) into the Circulation. Mol Cancer Res 15(9):1197-1205, 2017. e-Pub 2017. PMID: 28550083.
- Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA . Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol 145(3):462-468, 2017. e-Pub 2017. PMID: 28233576.
- Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA . Hormonal Based Treatment of Ovarian Anaplastic Ependymoma with Anastrozole. Gynecol Oncol Rep 20:93-96, 2017. e-Pub 2017. PMID: 28393092.
- Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A . MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med 35(22):3892-906, 2016. e-Pub 2016. PMID: 27112322.
- Ring KL, Pakish J, Jazaeri AA . Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer J 22(2):101-107, 2016. PMID: 27111905.
- Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA , Huang Z, Murphy SK, Mythreye K. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia 17(11):826-38, 2015. PMID: 26678910.
- Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA , Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget 6(30):30194-211, 2015. PMID: 26327203.
- Scalici JM, Harrer C, Allen A, Jazaeri A , Atkins KA, McLachlan KR, Slack-Davis JK. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol 132(2):455-61, 2014. e-Pub 2013. PMID: 24378876.
- Jividen K, Movassagh MJ, Jazaeri A , Li H. Two methods for establishing primary human endometrial stromal cells from hysterectomy specimens. J Vis Exp(87), 2014. e-Pub 2014. PMID: 24894444.
- Qiao Y, Quinlan AR, Jazaeri AA , Verhaak RG, Wheeler DA, Marth GT. Subclone Seeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol 15(8):443, 2014. e-Pub 2014. PMID: 25160522.
- Jazaeri AA , Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 12(10):1958-67, 2013. e-Pub 2013. PMID: 23939375.
- Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A , Risinger JI, Rubin JS, Niederhuber J. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene 32(27):3246-53, 2013. e-Pub 2012. PMID: 22890324.
- Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, Jazaeri AA , Cantrell LA, Duska LR. Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. Gynecol Oncol Case Rep 5:6-9, 2013. e-Pub 2013. PMID: 24371682.
- Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA. Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol 126(1):20-4, 2012. e-Pub 2012. PMID: 22522190.
- Jazaeri AA , Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 13(10):899-911, 2011. PMID: 22028616.
- Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA , Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol 121(1):2-7, 2011. e-Pub 2011. PMID: 21269667.
- Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA . Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol 116(6):1348-53, 2010. PMID: 21099601.
- Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A , Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 9(21):4387-98, 2010. e-Pub 2010. PMID: 20980827.
- Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol 118(2):189-95, 2010. e-Pub 2010. PMID: 20462630.
- Greene DP, Ferriss JS, Jazaeri AA . Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother Pharmacol 66(2):265-7, 2010. e-Pub 2009. PMID: 19844714.
- Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, Jazaeri AA . Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer 20(1):120-5, 2010. PMID: 20130512.
- Terai K, Abbas T, Jazaeri AA , Dutta A. CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell 37(1):143-9, 2010. PMID: 20129063.
- Jazaeri AA, Slack-Davis JK. The promise of antiangiogenic therapy for ovarian cancer. Cancer Biol Ther 8(23):2273-4, 2009. e-Pub 2009. PMID: 19907207.
- Jazaeri AA . Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol 3(2):151-6, 2009. e-Pub 2009. PMID: 19383376.
- Bland AE, Stone R, Heuser C, Shu J, Jazaeri A , Shutter J, Atkins K, Rice L. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer 19(2):261-5, 2009. PMID: 19396006.
- Lachance JA, Shutter J, Atkins KA, Stoler MH, Rice LW, Jazaeri AA . Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol 199(2):189.e1-6, 2008. e-Pub 2008. PMID: 18501326.
- Darus CJ, Callahan MB, Nguyen QN, Pastore LM, Schneider BF, Rice LW, Jazaeri AA . Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer 18(4):730-5, 2008. e-Pub 2007. PMID: 17949426.
- Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 109(1):140-5, 2008. e-Pub 2008. PMID: 18275990.
- Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA . A cost comparison of two strategies for treating stage IB2 cervical cancer. Int J Gynecol Cancer 18(2):274-8, 2008. PMID: 18334009.
- Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA . A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol 108(1):77-83, 2008. e-Pub 2007. PMID: 17936341.
- Modesitt SC, Jazaeri AA . Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 8(14):2293-305, 2007. PMID: 17927484.
- Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol 197(2):195.e1-7; discussion 195.e7-8, 2007. PMID: 17689647.
- Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA . Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197(2):199.e1-4; discussion 199.e4-5, 2007. PMID: 17689649.
Invited Articles
- Bae-Jump V, Jazaeri AA . Summary of the 2012 American Association for Cancer Research (AACR) Annual Meeting 126(2):174-5, 2012.
Editorials
- Nelson BH, Jazaeri AA . Immunotherapy for gynecological cancers: opportunities abound. Gynecol Oncol 145(3):411-412, 2017. PMID: 28552394.
- Zamarin D, Jazaeri AA . Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 141(1):86-94, 2016. PMID: 27016233.
Abstracts
- Odunsi K, Cristea M, Dorigo O, Jazaeri AA, Slomovitz B, Chagin K, Van Winkle E, Kari G, Iyengar M, Norry E, Pandite L, Amado R. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer. Proceedings of the 2017 Annual American Society of Clinical Oncology Annual Meeting, 2017.
- Colbert L, Dorta-Estremera S, Previs R, Eifel P, Jhingran A, Ramondetta L, Hahn S, Welsh J, Jazaeri A, Frumovitz M, Sastry J, Klopp A. Effect of chemoradiation for cervical cancer on transient decrease and variable expansion in T-cell infiltrate and diversity of T-cell repertoire. Proceedings of the 2017 Annual American Society of Clinical Oncology, 2017.
- Roszik J, Qin Y, Ekmekcioglu S, Forget M, Hwu P, Grimm E,Jazaeri AA. The neoantigen landscape and immune regulators in cervical cancer. Proceedings of the 2017 Annual American Society of Clinical Oncology Annual Meeting, 2017.
- Naing A, Lopez-Berestein G, Fu S, Tsimberidou A, Pant S, Piha-Paul S, Janku F, Hong D, Sulovic S, Meng X, Jazaeri AA, Ng C, Karp D, Subbiah V, Meric-Bernstam F, Mitra R, Wu S, Sood A, Coleman R. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Proceedings of the 2017 Annual American Society of Clinical Oncology Annual Meeting, 2017.
- Vankayalapati H, Yerramreddy V, ZHou J, Handler J, Appalaneni R, Kancherla R, Wu R, Takemori H, Whitehurst A, Jazaeri AA, Coleman R, Lu Z, Bast R. Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers. Proceedings of the 2017 American Association for Cancer Research Annual Meeting, 2017.
- Khawaja M, Nick A, Jazaeri AA, Madhusudanannair V, Ng C, Janku F, Piha-Paul S, Soliman P, Fu S, Hong D, Karp D, Subbiah V, Tsimberidou A, Coleman R, Sood A, Meric-Bernstam F, Lu K, Naing A. Dose Expansion Study of Temsirolimus in Combination with Metformin in Patients with Advanced Endometrial Cancers. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016.
- Pakish J, Zhang Q, Jazaeri AA, Celestino J, Kwan S, Mok S, Yates M, Lu K. Endometrial cancer subtypes and immunotherapy: Is the immune microenvironment different in microsatellite instable endometrial cancers?. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016.
- Naing A, Lopez G, Fu S, Tsimberidou A, Kato SM, Piha-Paul S, Janku F, Hong D, Nick A, Jazaeri AA, Ng C, Karp D, Subbiah V, Meric-Bernstam F, Sood A, Coleman R. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A Phase I clinical trial. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016.
- Jazaeri AA, Paquette C, Kelting S, Stoler M, Zhang Q, Yates M, Creasy C, Bernatchez C,. Prognostic and Biologic Significance of High LCK Expression in Ovarian Cancer. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016.
- Sakellariou-Thompson D, Haymaker C, Forget M, Jazaeri AA, Hwu P, Bernatchez C.. Preclinical development of tumor infiltrating lymphocyte therapy for ovarian cancer. 30th Annual Meeting of the Society of Immunotherapy of Cancer, 2015.
- Jazaeri AA, Paquette,C., Kelting,S..Stoler,M., Zhang,Q., Yates,M., Creasy,C.. Bernatchez,C., Hwu.P.. Prognostic and Biologic Significance of High LCK Expression in Ovarian Cancer. 30th Annual Meeting of the Society of Immunotherapy of Cancer, 2015.
Book Chapters
- Ring KL, Brown J, Jazaeri AA . Ovarian Cancer. In: The MD Anderson Manual of Medical Oncology. Third Edition, 2016.
- Maxwell GL, Jazaeri AA , Rice LW.. “Hormones in Gynecologic Malignancies and Hormone Replacement Therapy”. In: Principles and Practice of Gynecologic Oncology. Fifth Edition, 2009.
- Nitecki R, Cobb L, Rauh-Hain A, and Jazaeri AA. Ovarian Cancer. In: The MD Anderson Manual of Medical Oncology. Fourth Edition. McGraw-Hill.
Grant & Contract Support
| Date: | 2022 - 2028 |
| Title: | Discovery of novel targets to improve ovarian cancer immunotherapy |
| Funding Source: | The Mark Foundation ASPIRE 1 |
| Role: | Co-Principal Investigator |
| ID: | FP00015420 |
| Date: | 2022 - 2025 |
| Title: | Targeting Ovarian Cancer Minimal Residual Disease (MRD) Using Immune and DNA Repair Directed Therapies |
| Funding Source: | Break Through Cancer |
| Role: | Principal Investigator |
| Date: | 2021 - 2026 |
| Title: | Exploiting the vulnerability of autophagic ovarian cancer cells to ALK and PARP inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Advisor |
| Date: | 2021 - 2024 |
| Title: | Enabling Liquid Biopsy-based HRD Assessment for Guiding PARP Inhibitors in Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Date: | 2021 - 2024 |
| Title: | RNA Mutations in Extracellular Vesicles as Complementary Biomarkers to Cell-Free DNA Mutations for Minimal Residual Disease Detection |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Date: | 2020 - 2023 |
| Title: | Harnessing the Power of the Immune System to Combat Ovarian Cancer |
| Funding Source: | Dunwoody/Reese Ovarian Cancer Research |
| Role: | Principal Investigator |
| Date: | 2019 - 2021 |
| Title: | Immunogenomic analysis of MSI-H endometrial to identify biomarkers of response and novel therapeutic targets |
| Funding Source: | UTMDACC SPORE in Uterine Cancer Developmental Research Award |
| Role: | Principal Investigator |
| Date: | 2019 - 2024 |
| Title: | Cancer Center Support (Core) Grant |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| ID: | P30CA016672 |
| Date: | 2018 - 2021 |
| Title: | Intraperitoneal immune checkpoint blockade as a novel approach to reverse the immunosuppressive tumor microenvironment in patients with ovarian cancer and peritoneal carcinomatosis |
| Funding Source: | Emerson Collective |
| Role: | Principal Investigator |
| Date: | 2018 - 2020 |
| Title: | A pilot investigation of the ability of liquid biopsies to predict residual at second look surgery in ovarian cancer |
| Funding Source: | UTMDACC SPORE in Ovarian Cancer Developmental Research Award |
| Role: | Principal Investigator |
| Date: | 2017 - 2024 |
| Title: | NIH SPORE in Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| ID: | P50 CA217685 |
| Date: | 2017 - 2022 |
| Title: | Phase I/II Study to Evaluate Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ MAGEA4-Specific T Cells in Combination with Anti-CD137 Antibody for Patients with Advanced Ovarian Cancer |
| Funding Source: | City of Hope National Medical Center |
| Role: | Collaborator |
| ID: | FP00002043 |
| Date: | 2015 - 2024 |
| Title: | Clinical and Translational Evaluation of Tumor Infiltrating Lymphocyte Immunotherapy for Ovarian Cancer (Start up) |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| ID: | 115682 |
Patient Reviews
Comments (55)
My appointment with Dr. Jazaeri was wonderful. He is very kind and I'm just so blessed to have all of the wonderful staff in his care. I just would like to comment that the staff at Dr. Jazaeri's office and the staff from [...] office were so kind and I was able to see all...
Excellent!
Caring. Thorough. Professional.
I did learn a lot in a short time and things were explained to me thoroughly and so I could understand which I appreciated. Dr Jazaeri and resident Dr. Kim were aware of my case and reviewed my records thoroughly. The thoracentesis procedure was done with ease and I am glad...
I would no trade for my doctor. He is calm and caring person with my health status his main concern.
Dr. Jazaeri is the best!
I appreciate Dr. Jazaeri and my team looking for new treatments options to try. I feel that I am in good hands and leave my appointments well informed.
Dr Jazaeri and my care team are my support and direction. They are always pro-active and responsive. They are very watchful.
My provider from day one instilled confidence in my treatment plan. Almost two years later, my provider continues to be dedicated to making sure his patients , including me, are given the best evidence based plan of care , he can give. Treats me with respect and is ready to...
I was extremely happy with everyone who participated in the care I received.
He was very kind and obviously knows his field. What I didn't feel is that we looked at my results and individual needs. He made my diagnosis scary, and didn't instill a feeling of hope. Which made me even more hesitant to bother doing the chemotherapy.
Gifted surgeon and oncologist. A hero in my eyes. He's beyond intelligent, very approachable, professional, compassionate, and trustworthy on top of my treatment and results. 1000/10.
I really liked the fact that he was attentive and listened to me.
Dr. Jazaeri is an awesome oncologist and I feel so blessed to be under his care. His expertise is shared in a very professional, kind, empathetic, and caring manner. He listens intently and really hears and interprets what I say. M D Anderson is fortunate to have him on...
Always attentive to my health issues and questions So proactive in my medical issues Has always made me feel I could not be in better care
I was more than satisfied and my expectations were exceeded.
I am very with happy with service and treatment I got it from MDANDERSON. Thank god I came to mdanderson . I really appreciate everything. Excellent treatment from both Dr .
I'm very satisfied with my team. There have been several times when scheduling has been a problem the team has worked and got things managed. My family will also keep the team updated.
Hi. I am just so thrilled with the services that I got from MD Anderson. The doctors, Dr. Jazaeri, Dr. Grabber-Williams, I have no words for that. They are excellent, excellent, and definitely I'm going to recommend to my friends and family. And thank you so much for the...
Most grateful for Dr. Jazaeri and his team. Thank you! They truly CARE
Dr. Jazaeri is great! I really appreciate him and his care of my cancer. Occasionally, when I go in for a routine check-up and treatment, I don't see Dr. Jazaeri. This is always concerning for me.I much prefer to see Dr. Jazaeri.
This was an initial visit to MDA for a second opinion. It was a very thorough visit and the provider told me there are possibly clinical trials that I might qualify for. This was very hopeful news
My experience was great from the time I arrived for my visit. That started from signing in and being weighed and put into a room to wait.
MD Anderson's team is superb!!!
I always love talking to my provider he is very informative any questions he answers or get the information you need
Very caring, very professional
I came to MDA for a second opinion and was so relieved that Dr. Jazaeri agreed with my oncologist in New Orleans. He recommended vaginal radiation that my doctor will also do. I will have 3 month check ups at MDA. This gives me peace of mind.
Dr. Jazaeri and his team are excellent. Dr. Jazaeri is kind, patient, and listens intently with respect to my questions and information that I share. If someone has to go on this journey, they should be so blessed as I am to have Dr. Jazaeri as their doctor. He is better...
He seemed preoccupied.
Yes, I saw Dr. Amir Jazaeri and his team and they are very professional, they are empathetic. He has the best bedside manner of any doctor I have ever visited. He is not one of my favorites, he is my favorite doctor and I would hope that anyone who has to take this journey...
Dr. Jazaeri is the best!!
Outstanding provider!
I receive excellent care from Dr. Jazaeri.
His assistant/practicioner spent time with me - the doctor spent only a few minutes. I had questions about the abrupt change in treatment that were not answered - my fault. Couldn't process the Information that fast.
Dr Jazaeri is extremely knowledgeable yet discusses my cancer and treatment so that I understand. He is compassionate and cares about me as a person. I am so thankful that he is my doctor.
My experience with MD Anderson and Dr. Jazaeri in particular has been wonderful. Everybody has been top-notch. I feel very special, very well taken care of and I highly recommend anybody going through any medical issue to go to MD Anderson.
Everything and everyone at MD Anderson have been phenomenal. Such blessing from everyone you meet.
My Doctor and All Staff all very caring
I've been under the care of Dr. Jazaeri for the past two and a half year. I have nothing but gratitude and respect for his kindness, compassion and professionalism. He is simply an amazing human being! Big shoutout to his great team. I'm so grateful for every one of them!!!
Even though I was saddened that I learned my cancer had returned, all the nurses and Dr, Jazeuri assured me that we had caught it early and would be able to control it, which was stress-reducing for me
Dr. Jazaeri was professional, approachable, and clearly explained options and possibilities for my ongoing treatment. (I have ovarian cancer and have completed frontline therapy. The medical assistants (or P.A.s?) were professional, friendly and thorough.
Awesome wish we can continue without financial barrier.
Dr Jazeri was very informative and delivered information on a clear and gentle manner
He and the team are first very knowledgeable of my cancer are the best equipped to help me. I feel that trust and respect. We will work together!
He made me feel that I was in the right place for my particular problem.He was knowledgeable, professional and explained things clearly. It was great having him for my doctor. I look forward to my next visit with him.
My care provider was great.
I feel MD Anderson employee's are caring people.
Great
He always is fairly prompt, and gives me adequate time to ask questions about my results and condition. I respect him and his time as well.
Very pleased
CV information above last modified March 20, 2024